Tesamorelin — Stabilised GHRH Analogue (EGRIFTA)

Regulatory note. Tesamorelin (EGRIFTA / Egrifta SV) is FDA-approved solely for HIV-associated lipodystrophy. All other uses discussed below are investigational. This page is for informational and research purposes only — not medical advice.

Discovery and Development

Tesamorelin emerged from research conducted by the Canadian biopharmaceutical company Theratechnologies in the early part of this century. The clinical unmet need was clear: a significant proportion of people living with HIV who were maintained on antiretroviral therapy developed dyslipidaemia and central visceral fat accumulation — a condition broadly termed HIV-associated lipodystrophy. This metabolic complication was strongly associated with heightened cardiovascular risk, social stigma, and reduced treatment adherence.

Earlier attempts to correct the GH axis in this population used recombinant human growth hormone (rhGH) directly, but supraphysiological GH administration carried disproportionate side-effect burdens including oedema, arthralgia, and insulin resistance. Theratechnologies took a different approach: rather than supplementing GH directly, they designed a molecule that would stimulate the patient's own pituitary to release GH in a more physiological pulsatile fashion.

The result was TH9507, later named tesamorelin. Its development culminated in a successful Phase III programme and FDA approval of EGRIFTA in November 2010 — marking it as the first and, to date, only GHRH analogue to achieve regulatory approval anywhere in the world. A reformulated version, Egrifta SV (stabilised version), was subsequently approved to reduce storage and handling complexity.

Mechanism of Action

Tesamorelin is a synthetic analogue of endogenous growth hormone-releasing hormone (GHRH), structurally equivalent to the full forty-four amino acid sequence of native GHRH but carrying a trans-3-hexenoyl fatty acid moiety conjugated to the N-terminus. This single structural modification dramatically extends the peptide's resistance to dipeptidyl peptidase IV (DPP-IV) cleavage, which is the primary route of inactivation for native GHRH in plasma. While native GHRH has a plasma half-life of under two minutes, tesamorelin's plasma half-life is approximately 26 minutes.

Critically, the trans-3-hexenoyl modification does not materially alter receptor binding pharmacology. Tesamorelin binds with high affinity to the pituitary GHRH receptor (GHRHR), activating adenylyl cyclase, raising intracellular cyclic AMP, and triggering GH synthesis and pulsatile release from somatotroph cells. This preserved physiological pulsatility is what distinguishes GHRH-based strategies from exogenous rhGH: the GH axis remains subject to normal somatostatin-mediated negative feedback, preventing the runaway IGF-1 elevation seen with direct GH administration.

Downstream, elevated GH promotes lipolysis in adipocytes with a preferential effect on visceral adipose tissue (VAT). The precise mechanistic basis for visceral selectivity is not fully resolved, but it is thought to reflect the higher density of GH receptors in omental and mesenteric fat depots, combined with the greater sensitivity of visceral adipocytes to GH-mediated lipolytic signals. In Phase III trials, tesamorelin reduced VAT by approximately 15–18% versus baseline (roughly 30% versus placebo) at 26 weeks, without equivalent changes in subcutaneous fat [PMID:18057338].

The pharmacological effect on GH and IGF-1 persists substantially beyond the 26-minute plasma half-life because pituitary GHRHR stimulation initiates a secretory cascade that unfolds over hours. Single evening injections achieve an amplification of nocturnal GH pulses that physiologically mirrors the dominant GH secretory window in healthy individuals.

Researched Applications

HIV-associated lipodystrophy (approved indication): The EGRIFTA Phase III programme enrolled several hundred HIV-positive adults on stable antiretroviral therapy with documented excess visceral fat. The pivotal Falutz et al. trial published in the New England Journal of Medicine demonstrated statistically significant VAT reduction at 26 weeks alongside improvements in patient-reported body image and trunk-to-limb fat ratio [PMID:18057338]. A subsequent 26-week extension confirmed maintenance of effect with continued treatment and partial reversal on discontinuation [PMID:20400884].

Non-alcoholic fatty liver disease (NAFLD/MASLD): An investigational trail has explored tesamorelin in people with HIV and hepatic steatosis. A randomised controlled study by Fourman and colleagues reported a significant reduction in liver fat fraction assessed by magnetic resonance spectroscopy, alongside improvements in hepatic fibrosis markers [PMID:31917347]. A parallel study by Stanley et al. demonstrated improvements in liver fat content and adiponectin in HIV-positive adults [PMID:22564667]. These findings have prompted interest in whether GHRH-receptor agonism could address MASLD in non-HIV populations, though no large trials have yet reported in that cohort.

Cognitive ageing and neurodegenerative risk: Smaller exploratory studies have examined whether optimising the GH/IGF-1 axis via tesamorelin improves cognitive performance in older adults. Preliminary data suggest potential benefits in executive function and verbal memory, consistent with the known role of IGF-1 in hippocampal neurogenesis. This area remains early-stage.

Metabolic syndrome and cardiovascular risk: Post-hoc analyses from the HIV trials noted improvements in triglyceride levels and C-reactive protein, outcomes of interest beyond the HIV-specific setting [PMID:25971853].

Dosing and Administration

The approved dose is 2 mg administered as a single subcutaneous injection daily, typically into the abdominal wall. Some investigational protocols have used 1 mg/day in participants deemed more sensitive to GH axis stimulation (older adults, lower baseline IGF-1) or where tolerability is a primary concern.

Evening administration is conventional and pharmacologically rationale: injecting approximately one hour before sleep coincides with the natural nocturnal GH secretory window, allowing tesamorelin to amplify endogenous pulsatility rather than compete with it. Injection sites should be rotated across the periumbilical abdominal region to minimise local lipohypertrophy.

Treatment duration in approved HIV-lipodystrophy protocols is typically 26–52 weeks, with periodic re-evaluation of VAT. Discontinuation produces a gradual partial return of visceral fat over ensuing weeks, suggesting maintenance therapy may be required for durable effect.

Safety and Monitoring

Tesamorelin's side-effect profile reflects both its mechanism and the populations studied:

Fluid retention and oedema: Peripheral oedema, arthralgia, and myalgia occur more frequently than with placebo and are consistent with GH-mediated sodium and water retention. These effects are typically mild to moderate and transient. Dose reduction to 1 mg may attenuate them.

Paraesthesia: Tingling or numbness, particularly in the hands, is reported by a meaningful minority of users and likely reflects GH-associated carpal tunnel-equivalent fluid shifts in nerve sheaths.

Glucose metabolism: GH physiologically antagonises insulin action. Tesamorelin produces small but measurable elevations in fasting glucose and HbA1c in some users. Individuals with pre-existing impaired glucose tolerance or established type 2 diabetes should be monitored carefully; the benefit-risk balance in these subgroups requires individual assessment [PMID:24859837].

IGF-1 monitoring: IGF-1 should be measured at baseline and after 4–8 weeks of treatment. Sustained IGF-1 elevation above age- and sex-adjusted reference ranges warrants dose reduction or temporary interruption. Chronic supraphysiological IGF-1 is associated with theoretical risks of neoplastic stimulation, though no causal evidence exists from tesamorelin clinical data at approved doses.

Contraindications: Active malignancy, known hypersensitivity to GHRH or tesamorelin, pregnancy, and disrupted hypothalamic-pituitary axis secondary to surgery, trauma, or radiation are standard contraindications. Tesamorelin is not appropriate where GH excess (acromegaly) exists or is suspected.

UK Regulatory Position

Tesamorelin does not hold marketing authorisation in the United Kingdom or the European Union. EGRIFTA's approval is specific to the US FDA. In the UK, prescribers wishing to use tesamorelin for a licensed indication (HIV-associated lipodystrophy) in exceptional circumstances may apply via the MHRA Specials route or access it through Named Patient Supply arrangements, but these pathways involve case-by-case approval and are not routine.

Outside the HIV-lipodystrophy indication, tesamorelin is classified as a research compound in the UK. Supply and possession for personal use without prescription is a grey area under the Medicines Act 1968, and no specific exemption analogous to the US compounding pathway applies. Researchers operating under institutional ethics approval may handle the compound under relevant frameworks, but recreational or unsanctioned clinical use carries regulatory and safety risks that prospective users should understand fully before proceeding.

Reconstitution

Tesamorelin is supplied as a lyophilised powder requiring reconstitution with sterile water for injection. The Egrifta SV formulation uses a pre-filled diluent cartridge system; compounded versions typically require manual reconstitution.

Standard procedure: allow the vial to reach ambient temperature, then inject the supplied sterile water gently against the inside wall of the vial. Swirl gently — do not shake, as mechanical agitation denatures peptide bonds and reduces potency. The reconstituted solution should appear clear to slightly opalescent. Inspect for particulates before use and discard if present. Once reconstituted, the solution should be refrigerated at 2–8°C and used within 24 hours per manufacturer guidance; compounded preparations may specify different stability windows based on excipient composition.

Frequently Asked Questions

How does tesamorelin differ from CJC-1295? Both are GHRH analogues, but they differ substantially in structure and half-life. CJC-1295 with DAC incorporates a drug affinity complex that binds to albumin, extending plasma half-life to days and producing sustained rather than pulsatile GH elevation. Tesamorelin retains a pharmacokinetic profile closer to native GHRH and preserves pulsatility more faithfully. The clinical implications — particularly regarding long-term IGF-1 stability and physiological GH secretory patterns — are a matter of ongoing research interest.

Can tesamorelin be stacked with a GHRP or ghrelin mimetic? Combining GHRH-axis peptides with ghrelin receptor agonists (such as ipamorelin or hexarelin) to achieve synergistic GH release is a common investigational strategy, and tesamorelin is no exception. The GHRH and ghrelin axes act through distinct pituitary mechanisms and have demonstrated additive effects in research settings. However, stacking amplifies both efficacy and the risk of side effects (particularly glucose and IGF-1 perturbation), requiring more attentive monitoring.

Is tesamorelin useful for body composition outside the HIV context? The mechanistic case is plausible: visceral fat reduction via GH axis stimulation is not inherently HIV-specific. Small studies and case series suggest similar anthropometric benefits in non-HIV populations with central adiposity. However, no Phase III evidence exists in the general population, and the regulatory apparatus that would accompany such use is absent. Extrapolating from the HIV data is biologically reasonable but clinically unvalidated.

How quickly does VAT reduction become apparent? In clinical trials, statistically significant VAT reductions were measurable by 26 weeks, with meaningful changes emerging from around 8–12 weeks in responders. Individual variability is significant and correlates with baseline GH axis function, baseline VAT burden, and adherence.

---

Related Stacks

• CJC-1295 / Ipamorelin / Tesamorelin GH Stack — combining GHRH and ghrelin-axis peptides for synergistic GH release
• Tesamorelin + AOD-9604 Visceral Fat Stack — dual-mechanism approach targeting central adiposity via GH axis and lipolytic GH fragment

Related on this site

• CJC-1295 vs Tesamorelin — evidence comparison
• GH axis mechanism map
• GHRH receptor (glossary)
• Unlicensed medicines & 'Specials' explained
• CJC-1295 + Ipamorelin + Tesamorelin — combination evidence review
• Tesamorelin + AOD-9604 visceral adipose research review

Regulatory and clinical status

UK status: FDA-approved (EGRIFTA, 2010) for HIV-associated lipodystrophy. EU/UK availability limited. Outside this indication, research use only.

Read more about how UK regulation applies to peptides in our UK regulation hub and our explanation of what “research use only” means in the UK. PeptideStacks does not make editorial sourcing recommendations within research content; any vendor links elsewhere on this page appear in a clearly-labelled sponsor block (see our conflict-of-interest disclosure).

References

Peer-reviewed sources for the claims above. Where an editor has verified study type, sample size, outcome and limitation, the citation is rendered as a card; otherwise as a plain reference. Links open PubMed or the journal DOI.

Metabolic effects of a growth hormone-releasing factor in patients with HIV

Falutz J, Allas S, Blot K, et al. · New England Journal of Medicine · 2007, 357(23), 2349-2359

Randomised controlled trialEvidence weight: high

Model

Humans — HIV-positive adults on stable antiretroviral therapy with excess visceral fat

Sample size

n = 412 randomised 2:1 to tesamorelin 2 mg sc daily vs placebo

Compound(s)

Tesamorelin

Route in study

Subcutaneous, once daily, 26 weeks

Outcome measured

Change in visceral adipose tissue (VAT) by CT at week 26

Main finding

Mean VAT reduction of ~15% vs +5% with placebo at 26 weeks; statistically significant. IGF-1 rose into the upper-normal range without clinical hypoglycaemia.

Key limitation

Defined HIV-lipodystrophy population; effects do not generalise to non-HIV indications. 26-week duration limits long-term safety inference.

PubMed PMID:18057338

Reported in study context only — not a recommendation or protocol.

1. Falutz J, Mamputu JC, Potvin D, et al.. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat: a pooled analysis. AIDS. 2010;24(9) :1329-1337 · PMID: 20400884
2. Stanley TL, Feldpausch MN, Oh J, et al.. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation. Journal of Clinical Endocrinology & Metabolism. 2012;97(7) :2357-2366 · PMID: 22564667
3. Fourman LT, Czerwonka N, Feldpausch MN, et al.. Tesamorelin improves fat quality independent of changes in fat quantity. Clinical Gastroenterology and Hepatology. 2020;18(10) :2339-2348 · PMID: 31917347
4. Adrian S et al.. Growth hormone-releasing factor analogue in HIV-associated lipodystrophy. HIV Medicine. 2004;5(4) :278-284 · PMID: 15236617
5. Mansueto P, Seidita A, Vitale G, Carroccio A. Anti-aging medicine: a brief review. Journal of Endocrinological Investigation. 2015;38(9) :919-929 · PMID: 25971853
6. Spooner LM, Olin JL. Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy. Annals of Pharmacotherapy. 2012;46(2) :240-247 · PMID: 22238409
7. Dhindsa S, Furlanetto R, Vora M, et al.. Tesamorelin lowers insulin secretion and increases insulin sensitivity. Diabetes Care. 2014;37(8) :2176-2181 · PMID: 24859839

Published: 2026-05-16Last updated: 2026-05-16Last reviewed: 2026-05-16

Pages on PeptideStacks are reviewed when relevant new evidence becomes available. If you spot an error or have new evidence to suggest, please use our corrections policy.